HOBOKEN, N.J.--(BUSINESS WIRE)--For the second year in a row, Octapharma USA will serve as the exclusive sponsor of “Making the Connection,” a national conference for patients with Type 3 von Willebrand Disease (VWD).
VWD affects up to 1 percent of the U.S. population. Type 3 VWD is the rarest and most severe form of the condition.
“We will bring together patients and their guests with a world class group of physicians and medical professionals in a safe and relaxed environment for making lifetime connections and sharing educational information,” said conference organizer, Jeanette Cesta, President, VWD Connect Foundation. “We thank Octapharma USA for supporting the conference with an educational grant and helping us create a truly special event for the Type 3 VWD community.”
Educational information and other resources will be provided on various medical issues, such as treatment alternatives, joint health, symptoms and diagnosis. Family and professional relationships, challenges of loss and depression, disclosure issues, and positive coping strategies will be among the emotional and social topics on the agenda.
“Octapharma USA is committed to helping patients with chronic illnesses, such as Type 3 VWD, maximize their quality of life,” said Octapharma USA President Flemming Nielsen. “The first conference for Type 3 VWD patients was very well received and we are confident the program this year will build on that success. We are dedicated to programs and products that enable bleeding disorder patients to manage their condition.”
Physicians, healthcare providers specializing in bleeding disorders, geneticists, health educators, nurses, physical therapists, and social workers will be among the many professional resources available to conference attendees. For complete conference information, please visit www.VWDConnect.org.
About the VWD Connect Foundation
VWD Connect Foundation is a Florida-based non-profit organization created to serve the bleeding disorder community, focusing on severe von Willebrand Disease. It provides education and connection for patients and families, and supports research that will benefit the von Willebrand Disease community.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 7,600 people worldwide to support the treatment of patients in over 113 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.